A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
A 6-Month, Double-Blind, Phase 2 Study and 6-Month Open- Label Extension Evaluating the Safety, Tolerability, and Clinical Benefit of RPh201 in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
Sponsor: Regenera Pharma Ltd
A PHASE2 clinical study on Mild to Moderate Dementia Due to Alzheimer's Disease and With or Without Coexisting Cerebrovascular Disease, this trial is completed. The trial is conducted by Regenera Pharma Ltd and has accumulated 9 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
May 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jul 2019 — May 2020 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Aug 2018 — Jul 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Regenera Pharma Ltd
For direct contact, visit the study record on ClinicalTrials.gov .